What does Sight Sciences do?
Sight Sciences, Inc. is a Menlo Park–based ophthalmic medical-device company listed on the Nasdaq Global Select Market under SGHT. It develops single-use procedural technologies for two prevalent eye diseases: primary open-angle glaucoma and evaporative dry eye associated with meibomian gland dysfunction. The company’s central strategic idea is that eyecare can move from chronic symptom management toward interventions that address the eye’s natural drainage or tear-film physiology. That mission is reflected in its 2025 Form 10-K.
Which products define the portfolio?
A single-use, implant-free minimally invasive glaucoma surgery technology intended to address the trabecular meshwork, Schlemm’s canal, and distal collector channels. It can be used with cataract surgery or as a standalone procedure.
A sterile, single-use, bladeless instrument for excising trabecular meshwork. Its simpler goniotomy use case broadens the glaucoma portfolio and uses the same commercial call points as OMNI.
A SmartHub-and-SmartLid platform that applies localized heat while allowing natural blinking, followed by manual gland expression. The official TearCare product page describes the treatment focus on meibomian gland dysfunction.
The company is trying to create procedural categories rather than sell a broad catalogue. That supports high gross margins but makes training, reimbursement, clinical evidence, and coding central to the model.
How does Sight Sciences make money?
Sight Sciences earns product revenue when providers or facilities order disposable glaucoma instruments and dry-eye treatment components. OMNI and SION are sold mainly to ambulatory surgery centers and hospital outpatient departments according to expected procedure volumes. TearCare customers typically buy one or more reusable SmartHubs plus inventories of single-use SmartLids and accessories, then reorder SmartLids as procedures are performed. This creates a capital-light, recurring consumables model rather than a service, subscription, or implant-annuity model.
Which segment is the economic engine?
Glaucoma remains the cash-generating core. In FY2025 it produced $75.7 million, or 97.9% of total revenue, while dry eye contributed $1.6 million. The strategic tension is therefore clear: OMNI and SION must defend a mature, reimbursement-sensitive revenue base while TearCare must prove it can become a meaningful second growth engine.
| Revenue stream | Customer and transaction | FY2025 revenue | Economic driver |
|---|---|---|---|
| Interventional Glaucoma | Facilities order OMNI and SION for expected procedure volume | $75.7M | Active accounts, utilization, average selling price, procedure coverage |
| Interventional Dry Eye | ECPs buy SmartHubs and reorder SmartLids | $1.6M | Reimbursement, active practices, treatments per account, SmartLid pricing |
| International | Direct operations in the U.K. and Germany plus European distributors | Less than 10% of Q1 2026 total | Regulatory access, distributor productivity, surgeon adoption |
What did the latest quarter show?
The quarter ended March 31, 2026 showed a return to double-digit top-line growth and a substantial improvement in dry-eye momentum. According to the company’s first-quarter 2026 results, total revenue increased 12.5% to $19.7 million. The accompanying Q1 2026 Form 10-Q provides the full balance-sheet and expense context.
Where did growth come from?
Glaucoma revenue rose to $18.3 million as ordering accounts and pricing improved, partly offset by lower utilization per account. Dry-eye revenue reached $1.4 million from $0.4 million. Q1 2026 supplemental metrics were 1,175 glaucoma active customers, 1,534 SmartLids sold, and 96 dry-eye active customers.
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Operating expenses | $29.4M | $29.0M | Included a $5.4M one-time litigation success fee |
| Adjusted operating expenses | $21.2M | $24.7M | Down 14%, indicating lower core spending |
| R&D expense | $2.5M | $4.4M | Down 42.5%; efficiency improved, but sustained innovation capacity remains important |
| SG&A expense | $26.8M | $24.5M | Up 9.5%, largely reflecting the litigation fee |
| Net loss per share | $(0.24) | $(0.28) | Loss narrowed despite the one-time fee |
Why are reimbursement and procedure adoption the core strategy?
FDA clearance is only the first step: physicians must learn the procedures, facilities must stock the devices, and payors must reimburse them. OMNI can be used with cataract surgery or standalone; the company estimates standalone patients represent more than 85% of the potential U.S. primary open-angle glaucoma market.
Glaucoma: defend combination procedures and activate standalone use
The glaucoma strategy is to add ordering facilities, improve utilization, sustain pricing, and expand standalone use. OMNI’s implant-free design and three-part outflow-pathway approach differentiate it from stents and simpler devices, while SION adds a narrower goniotomy instrument.
Dry eye: convert reimbursement progress into recurring utilization
TearCare shows why reimbursement is decisive. Sight Sciences shifted from a primarily patient-pay approach in late 2024 toward reimbursed access. Two Medicare contractors established jurisdiction-wide pricing in Q4 2025. The next test is broader coverage, more active practices, and repeat SmartLid orders.
Health-economic evidence strengthens that case. The 2025 annual report cited an analysis in which TearCare produced estimated annual per-patient costs of $4,916 versus $5,819 for cyclosporine, a $903 difference, with slightly higher modeled quality-adjusted life years. Those results do not guarantee coverage, but they address the payor’s central question: whether a procedure improves outcomes at an acceptable total cost.
What strategic turning points shaped Sight Sciences?
The company’s history is best understood as a sequence of regulatory, product, and market-access milestones that progressively expanded the addressable procedures and commercial toolkit.
-
2010–2011Sight Sciences was incorporated in Delaware in 2010, and co-founder Paul Badawi has served as president, CEO, and a director since the company was founded in 2011. Founder continuity still shapes product strategy and governance.
-
2017OMNI received its initial FDA clearance. This established the platform that would become the company’s dominant revenue source.
-
2021The FDA cleared an expanded OMNI indication covering standalone and combination-cataract use across adult primary open-angle glaucoma. The company also completed its IPO, adding capital for commercialization.
-
2021TearCare received FDA clearance for localized heat therapy used with manual expression in adult evaporative dry eye due to meibomian gland dysfunction, creating the second operating segment.
-
2022SION launched as a bladeless goniotomy instrument, broadening the glaucoma offering without requiring a separate commercial infrastructure.
-
2024–2026Medicare coverage restrictions pressured glaucoma growth, while the dry-eye strategy pivoted toward reimbursement. By Q1 2026 revenue returned to double-digit growth, and a Delaware court judgment preserved a $55.4M past-damages award plus a 10% Hydrus royalty, subject to appeal.
What gives Sight Sciences a competitive advantage?
The company’s potential moat is a bundle of intellectual property, procedure design, clinical evidence, reimbursement work, physician education, and a specialized commercial organization. None is sufficient alone. Together, they can make it harder for a new entrant to match both the device and the surrounding adoption infrastructure.
Product differentiation and clinical positioning
OMNI’s broad mechanism and standalone indication support differentiation from glaucoma stents, while SION offers a bladeless alternative in goniotomy. TearCare’s blink-assisted localized heating and growing clinical package support a procedural argument against chronic prescription or over-the-counter approaches. The company highlighted additional OMNI and TearCare clinical presentations in its 2026 ASCRS release.
Where the moat is vulnerable
| Competitive factor | Sight Sciences position | Main pressure |
|---|---|---|
| Glaucoma devices | OMNI and SION cover canaloplasty, trabeculotomy, and goniotomy use cases | Glaukos, Alcon, AbbVie, Iantrek, New World Medical, and Nova Eye |
| Dry-eye procedures | TearCare targets meibomian gland dysfunction with a procedural treatment | Johnson & Johnson, Alcon, prescription therapies, and lower-cost alternatives |
| Commercial scale | Focused direct sales force with deep eyecare specialization | Larger rivals have broader portfolios, budgets, and customer relationships |
| Intellectual property | Patent portfolio and favorable trial judgment support negotiating leverage | Appeals, design-arounds, and continuing litigation costs |
The moat is therefore better described as specialized and evidence-based than dominant. It can support pricing and adoption, but it must be continually renewed through clinical publications, training, account activation, and favorable reimbursement.
How financially strong is Sight Sciences?
Sight Sciences combines high product gross margins with operating losses. Financial strength therefore depends on revenue growing faster than commercial, clinical, and corporate spending. FY2025 showed cost reduction; Q1 2026 showed better cash usage but not profitability.
Annual context: costs fell faster than revenue
FY2025 R&D declined to $14.6 million and SG&A to $89.2 million. The operating loss improved to $37.1 million, although operating cash use increased to $29.7 million as working capital became less favorable. Property purchases were only $0.2 million, confirming a low fixed-asset model.
Liquidity and capital allocation
| Balance-sheet item | March 31, 2026 | December 31, 2025 | Why it matters |
|---|---|---|---|
| Cash and cash equivalents | $85.0M | $92.0M | Provides runway while losses continue |
| Total assets | $109.7M | $115.3M | Mostly liquid current assets rather than fixed plant |
| Debt, net | $40.5M | $40.3M | Adds interest and refinancing obligations |
| Stockholders’ equity | $53.9M | $63.9M | Declined mainly because of the quarterly net loss |
| Accumulated deficit | $(397.7)M | $(384.7)M | Shows the cumulative cost of developing and commercializing the platform |
Management expects cash and available borrowing capacity to fund planned operations for at least 12 months. Valuation still depends on reducing burn before liquidity constrains strategy. Q1 2026 cash use of $7.0 million was better, but the improvement must persist.
Who owns Sight Sciences stock, and how is it governed?
Sight Sciences has one-vote-per-share common stock, but ownership is not fully dispersed. Founder-management and an affiliated investment group hold meaningful stakes. The 2026 proxy statement is the official source for these figures.
| Holder or group | Beneficial shares | Ownership | Governance implication, April 8, 2026 |
|---|---|---|---|
| Staffan Encrantz | 7,111,298 | 13.1% | Independent chair; stake includes Allegro-affiliated holdings |
| Paul Badawi | 6,840,140 | 12.3% | Co-founder, president, CEO, and director; strong alignment and key-person exposure |
| Allegro entities | 5,086,920 | 9.4% | Affiliated with the board chair; included within Encrantz’s reported beneficial ownership |
| Long Focus Capital Management | 3,126,508 | 5.7% | Meaningful external institutional influence |
| Directors and current executive officers | 17,225,662 | 30.4% | Collective insider influence is material, though holdings overlap with affiliated entities |
Board structure and incentives
Paul Badawi and Chief Technology Officer David Badawi are brothers and both sit on the board. Founder involvement can support long-horizon product development, but researchers should account for succession and concentration risk. The independent chair structure and majority-independent board provide counterweights. Equity compensation is also material: Q1 2026 stock-based compensation was $2.9 million, while 8.6 million potentially dilutive options, restricted stock units, and warrants were excluded from diluted EPS because the company was loss-making.
What opportunities and risks could change the story?
The upside case is a portfolio transition: durable glaucoma growth, broader standalone OMNI use, and reimbursed TearCare becoming a second consumables engine. FY2026 guidance is $83 million–$89 million, including $77 million–$81 million from glaucoma and $6 million–$8 million from dry eye.
The most material risk channels
Other risks include training quality, adverse outcomes, slower adoption, pricing pressure, regulation, debt covenants, cybersecurity, key-person dependence, and dilution. No customer represented 10% or more of FY2025 or Q1 2026 revenue, but product and reimbursement concentration remain significant.
Why does Sight Sciences matter for valuation?
A conventional earnings multiple has limited use while Sight Sciences is loss-making. A DCF should trace procedure adoption into gross profit, operating leverage, and sustainable free cash flow. Key assumptions are utilization, reimbursement breadth, segment mix, sales productivity, and required clinical and commercial spending.
The variables that drive intrinsic value
| Valuation driver | Current evidence | DCF implication |
|---|---|---|
| Revenue growth | Q1 2026 revenue grew 12.5%; FY2026 guidance implies 7%–15% | Tests whether the post-2024 reimbursement disruption is temporary or structural |
| Gross margin | 86.2% in FY2025 and Q1 2026 | Supports strong incremental gross profit if pricing and product costs remain stable |
| Operating leverage | Adjusted Q1 2026 operating expenses fell 14% | Determines when gross profit can cover the commercial and corporate cost base |
| Reinvestment | FY2025 R&D was $14.6M; property purchases were $0.2M | The model is research- and sales-intensive rather than fixed-asset-intensive |
| Financing risk | $85.0M cash and $40.0M debt principal at March 31, 2026 | Cash runway and future dilution affect equity value even before terminal assumptions |
| Legal optionality | $55.4M judgment plus 10% royalty, subject to appeal | Should be scenario-weighted separately from core operating cash flows |
A reasonable model should separate glaucoma and dry eye because they have different maturity, growth, margin, and reimbursement profiles. It should also distinguish GAAP operating expense from adjusted expense, include stock-based compensation dilution, and avoid treating litigation proceeds as recurring operating income.
What is the key takeaway from Sight Sciences analysis?
Sight Sciences is a focused eyecare technology company with a valuable high-margin glaucoma franchise and an early-stage dry-eye platform whose commercial outcome depends heavily on reimbursement. Q1 2026 delivered better growth, a 13% increase in total revenue on the company’s rounded presentation, stable 86% gross margin, lower adjusted operating spending, and improved cash usage. Those are meaningful signals, but the company still recorded a $13.0 million net loss and remains dependent on a narrow set of products and procedures.
What should researchers monitor next?
- Whether glaucoma revenue stays within the FY2026 guidance range of $77M–$81M and utilization per active account improves.
- Whether dry-eye revenue progresses toward the FY2026 guidance range of $6M–$8M rather than relying on one strong quarter.
- New Medicare or commercial coverage decisions for TearCare and the economics attached to those policies.
- Adjusted operating expense against the $93M–$96M FY2026 guidance range and the resulting cash burn.
- Gross-margin resilience against tariffs, product mix, and scaling costs.
- The appeal, collection, and royalty implications of the Alcon patent judgment.
- Share-count growth from options, restricted stock units, and ongoing equity compensation.
The central question is whether Sight Sciences can convert excellent unit economics and credible clinical differentiation into repeatable procedure growth before cash burn and competition erode strategic flexibility. OMNI and SION fund the story today; reimbursed TearCare adoption, standalone glaucoma expansion, operating leverage, and final resolution of the patent case determine how much larger and more durable that story can become.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.